2020
Parkinson’s disease treatment: past, present, and future
Elsworth JD. Parkinson’s disease treatment: past, present, and future. Journal Of Neural Transmission 2020, 127: 785-791. PMID: 32172471, PMCID: PMC8330829, DOI: 10.1007/s00702-020-02167-1.Peer-Reviewed Original Research
2000
Estrogen Is Essential for Maintaining Nigrostriatal Dopamine Neurons in Primates: Implications for Parkinson's Disease and Memory
Leranth C, Roth R, Elsworth J, Naftolin F, Horvath T, Redmond D. Estrogen Is Essential for Maintaining Nigrostriatal Dopamine Neurons in Primates: Implications for Parkinson's Disease and Memory. Journal Of Neuroscience 2000, 20: 8604-8609. PMID: 11102464, PMCID: PMC6773080, DOI: 10.1523/jneurosci.20-23-08604.2000.Peer-Reviewed Original ResearchConceptsNigrostriatal dopamine neuronsDopamine neuronsParkinson's diseaseSubstantia nigraDopamine cellsTyrosine hydroxylase-expressing neuronsTyrosine hydroxylase-immunoreactive cellsNigral dopamine systemsEstrogen replacement therapyNew treatment strategiesUnbiased stereological analysisTypes of neuronsProgression of diseaseEstrogen replacementPostmenopausal womenEstrogen deprivationReplacement therapyTreatment strategiesCompact zoneGonadal hormonesLong-term effectsDopamine systemEstrogenDiseaseNeurons
1998
In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector
During M, Samulski R, Elsworth J, Kaplitt M, Leone P, Xiao X, Li J, Freese A, Taylor J, Roth R, Sladek J, O’Malley K, Redmond D. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Therapy 1998, 5: 820-827. PMID: 9747462, DOI: 10.1038/sj.gt.3300650.Peer-Reviewed Original ResearchMeSH Keywords1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsAromatic-L-Amino-Acid DecarboxylasesChlorocebus aethiopsDependovirusDopamineDopamine AgentsGene ExpressionGene Transfer TechniquesGenetic VectorsHumansImmunohistochemistryMaleParkinson DiseaseTrigeminal Caudal NucleusTyrosine 3-MonooxygenaseConceptsTyrosine hydroxylaseStriatal cellsDopamine-depleted monkeysAdeno-associated virus vectorProduction of dopamineParkinsonian monkeysTransient feverSevere hyperactivityStriatal dopaminePrimate neuronsStereotactic injectionHistological evidencePrimate modelInjection tractNeurotoxin MPTPDopamine productionParkinson's diseaseTreatment groupsSignificant toxicityBehavioral effectsVivo gene therapyElevated levelsBiochemical effectsFirst dayMonkeys
1997
Dopamine Synthesis, Uptake, Metabolism, and Receptors: Relevance to Gene Therapy of Parkinson's Disease
Elsworth J, Roth R. Dopamine Synthesis, Uptake, Metabolism, and Receptors: Relevance to Gene Therapy of Parkinson's Disease. Experimental Neurology 1997, 144: 4-9. PMID: 9126143, DOI: 10.1006/exnr.1996.6379.Peer-Reviewed Original Research
1995
General Cognitive Ability Following Unilateral and Bilateral Fetal Ventral Mesencephalic Tissue Transplantation for Treatment of Parkinson's Disease
Sass K, Buchanan C, Westerveld M, Marek K, Farhi A, Robbins R, Naftolin F, Vollmer T, Leranth C, Roth R, Price L, Bunney B, Elsworth J, Hoffer P, Redmond D, Spencer D. General Cognitive Ability Following Unilateral and Bilateral Fetal Ventral Mesencephalic Tissue Transplantation for Treatment of Parkinson's Disease. JAMA Neurology 1995, 52: 680-686. PMID: 7619024, DOI: 10.1001/archneur.1995.00540310050016.Peer-Reviewed Original ResearchConceptsCognitive abilitiesNonverbal cognitive abilityVerbal cognitive abilityInformation-processing speedVerbal memoryNeuropsychological profileTest batteryCognitive functionNormal cognitive functionCognitive dysfunctionRight caudate nucleusCaudate nucleusFactor analysisTissue transplantationParkinson's disease
1993
Neural Transplantation for Neurodegenerative Diseases: Past, Present, and Futurea
REDMOND D, ROTH R, SPENCER D, NAFTOLIN F, LERANTH C, ROBBINS R, MAREK K, ELSWORTH J, SASS K, TAYLOR J, SLADEK J. Neural Transplantation for Neurodegenerative Diseases: Past, Present, and Futurea. Annals Of The New York Academy Of Sciences 1993, 695: 258-266. PMID: 8239293, DOI: 10.1111/j.1749-6632.1993.tb23064.x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrain Tissue TransplantationFetal Tissue TransplantationHumansParkinson DiseaseParkinson Disease, SecondaryConceptsNeural transplantationParkinson's diseaseDopamine neuronsCellular replacementClinical treatmentFetal cellsNeural tissue transplantsNeural tissueIdiopathic Parkinson's diseaseDopamine-producing cellsFunctional effectsBest medical treatmentFetal neural tissueImportant functional effectsHuman neural tissueEssential neuromodulatorDrug therapyIdiopathic diseaseClinical conditionsTherapeutic experimentsBrain cellsIneffective treatmentMedical treatmentTissue transplantsTransplantation
1992
Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease
Spencer D, Robbins R, Naftolin F, Marek K, Vollmer T, Leranth C, Roth R, Price L, Gjedde A, Bunney B, Sass K, Elsworth J, Kier E, Makuch R, Hoffer P, Redmond D. Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease. New England Journal Of Medicine 1992, 327: 1541-1548. PMID: 1435880, DOI: 10.1056/nejm199211263272201.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdultAntiparkinson AgentsCaudate NucleusCryopreservationCyclosporineDopamineFemaleFetal Tissue TransplantationHomovanillic AcidHumansMagnetic Resonance ImagingMaleMesencephalonMiddle AgedMotor ActivityParkinson DiseasePutamenStereotaxic TechniquesTomography, Emission-ComputedConceptsCase patientsParkinson's diseaseMesencephalic tissueCaudate nucleusHuman fetal ventral mesencephalic tissueFetal ventral mesencephalic tissueHuman fetal mesencephalic tissueContinued disease progressionFetal dopaminergic neuronsFetal mesencephalic tissueVentral mesencephalic tissueSevere Parkinson's diseaseOptimal drug therapySigns of parkinsonismMidbrain dopamine neuronsPositron emission tomographyMonths of evaluationAntiparkinsonian medicationUnilateral transplantationDrug holidayMore medicationsStriatonigral degenerationNeurologic functionDopaminergic neuronsDrug therapy
1991
Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls
Taylor J, Elsworth J, Roth R, Sladek J, Collier T, Redmond D. Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls. Experimental Brain Research 1991, 85: 335-348. PMID: 1893983, DOI: 10.1007/bf00229411.Peer-Reviewed Original ResearchConceptsCaudate nucleusBehavioral deficitsHealthy behaviorsFetal substantia nigra cellsFetal substantia nigraIdiopathic Parkinson's diseasePoverty of movementType of graftDays/weekSubstantia nigra cellsTime of sacrificePre-treatment levelsSN cellsSpecific behavioral effectsMPTP treatmentMPTP toxicityParkinsonian signsSubstantia nigraControl subjectsInitiation of movementBrain sitesLimb tremorParkinson's diseaseControl animalsMPTP
1990
Chapter 62 Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys
Taylor J, Elsworth J, Roth R, Collier T, Sladek J, Redmond D. Chapter 62 Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys. Progress In Brain Research 1990, 82: 543-559. PMID: 2290957, DOI: 10.1016/s0079-6123(08)62645-x.Peer-Reviewed Original ResearchConceptsCSF HVA levelsHVA levelsBehavioral recoveryCaudate nucleusSN graftsDopamine neuronsDopamine productionHVA/dopamine ratioCentral dopamine productionFetal substantia nigraStriatum of subjectsSubstantia nigra transplantsRelease of dopamineImproved parkinsonismHost striatumHost brainFetal graftsMPTP administrationParkinsonian signsTH immunohistochemistrySubstantia nigraDopamine ratioSmall graftsBehavioral deficitsGraft
1988
Biochemical analysis of caudate nucleus biopsy samples from parkinsonian patients
Goldstein M, Lieberman A, Helmer E, Koslow M, Ransohoff J, Elsworth J, Roth R, Deutch A. Biochemical analysis of caudate nucleus biopsy samples from parkinsonian patients. Annals Of Neurology 1988, 24: 685-688. PMID: 2904793, DOI: 10.1002/ana.410240517.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiopsyCaudate NucleusDopamineFemaleHomovanillic AcidHumansMaleMiddle AgedParkinson DiseaseTyrosine 3-MonooxygenaseConceptsBiopsy samplesAdrenal transplantationDopamine functionAutologous adrenal transplantationMetabolite homovanillic acidEnzyme tyrosine hydroxylaseConcentration of dopamineParkinsonian patientsTherapeutic responseHomovanillic acidParkinson's diseaseTyrosine hydroxylasePostmortem valuesBiochemical analysisBiochemical parametersPatientsTransplantationPostmortem changesDisease
1987
Reversal of Parkinsonism by Fetal Nerve Cell Transplants in Primate Braina
SLADEK J, COLLIER T, HABER S, DEUTCH A, ELSWORTH J, ROTH R, REDMOND D. Reversal of Parkinsonism by Fetal Nerve Cell Transplants in Primate Braina. Annals Of The New York Academy Of Sciences 1987, 495: 641-657. PMID: 2886092, DOI: 10.1111/j.1749-6632.1987.tb23706.x.Peer-Reviewed Original ResearchChapter 25 Transplantation of fetal dopamine neurons in primate brain reverses MPTP induced parkinsonism
Sladek J, Redmond D, Collier T, Haber S, Elsworth J, Deutch A, Roth R. Chapter 25 Transplantation of fetal dopamine neurons in primate brain reverses MPTP induced parkinsonism. Progress In Brain Research 1987, 71: 309-323. PMID: 3495818, DOI: 10.1016/s0079-6123(08)61833-6.Peer-Reviewed Original ResearchConceptsParkinsonian signsFetal neuronsCerebrospinal fluidTyrosine hydroxylase-positive neuronsFetal dopamine neuronsToxin-induced parkinsonismDopamine metabolite levelsAfrican green monkeysNigral tissuePositive neuronsGestational tissuesNeurochemical indicesSubstantia nigraDopamine neuronsGrowth of neuritesCaudate nucleusMotor impairmentParkinson's diseaseSevere symptomsPrimate brainThird monkeyImmunohistochemical observationsTransplantationGreen monkeysTherapeutic insights
1982
The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties
Elsworth J, Sandler M, Lees A, Ward C, Stern G. The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties. Journal Of Neural Transmission 1982, 54: 105-110. PMID: 6809891, DOI: 10.1007/bf01249283.Peer-Reviewed Original Research
1978
Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’
Elsworth J, Glover V, Reynolds G, Sandler M, Lees A, Phuapradit P, Shaw K, Stern G, Kumar P. Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’. Psychopharmacology 1978, 57: 33-38. PMID: 96466, DOI: 10.1007/bf00426954.Peer-Reviewed Original ResearchConceptsMonoamine oxidase B inhibitorsSelective monoamine oxidase B inhibitorNormal dietCheese effectB inhibitorHuman intestinal mucosaNormal human intestinal mucosaPressor responseOral tyraminePressor reactionDeprenyl administrationAdverse reactionsMonoamine oxidase AIntestinal mucosaOxidase AHuman plateletsPlatelet enzymeDeprenylComplete inhibitionVolunteersDietTyramineInhibitorsMucosaAdministration
1977
DEPRENYL IN PARKINSON'S DISEASE
Lees A, Kohout L, Shaw K, Stern G, Elsworth J, Sandler M, Youdim M. DEPRENYL IN PARKINSON'S DISEASE. The Lancet 1977, 310: 791-795. PMID: 71602, DOI: 10.1016/s0140-6736(77)90725-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDouble-blind crossover trialDoses of levodopaEarly morning akinesiaPeripheral decarboxylase inhibitorLevodopa-induced dyskinesiaTotal daily dosesMajority of patientsIdiopathic Parkinson's diseaseDose akinesiaUntreated patientsCrossover trialDosage reductionDaily dosesDecarboxylase inhibitorTherapeutic effectCheese effectLarge dosesPatientsLevodopaAlternate daysAkinesiaDeprenylDiseaseB inhibitor